Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 2/20 | 0.52 |
| ▸ | MAOB | P27338 | 2/20 | 0.52 |
| ▸ | CHRNB4 | P30926 | 3/20 | 0.51 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.51 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.51 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.51 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.48 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | SRC | P12931 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14578275 | 0.86 | CHRNB4 (0.57) | MAOAMAOBCHRNB4CHRNA3CHRNB2 | |
| SCHEMBL15075234 | 0.85 | MAOA (0.56) | MAOAMAOBCHRNB4CHRNA3CHRNB2 | |
| SCHEMBL2227823 | 0.85 | TP53 (0.50) | MAOAMAOBCHRNB4CHRNA3CHRNB2 | |
| Hydrochloric Acid SCHEMBL7946319 | 0.84 | MAOA (0.57) | MAOAMAOBCHRNB4CHRNA3CHRNB2 | |
| Hydrochloric Acid SCHEMBL3255185 | 0.83 | MAOA (0.50) | MAOAMAOBCHRNB4CHRNA3CHRNB2 | |
| SCHEMBL3184573 | 0.83 | MAOA (0.53) | MAOAMAOBCHRNB4CHRNA3CHRNB2 | |
| SCHEMBL10199163 | 0.83 | CARM1 (0.54) | MAOAMAOBCHRNB4CHRNA3CHRNB2 | |
| SCHEMBL13185263 | 0.83 | KDM4E (0.54) | MAOAMAOBCHRNB4CHRNA3CHRNB2 | |
| Hydrochloric Acid SCHEMBL7068211 | 0.82 | MAOA (0.54) | MAOAMAOBHRH3SRC | |
| SCHEMBL25060110 | 0.82 | MAOA (0.50) | MAOAMAOBCHRNB4CHRNA3CHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3189059-B1 | THIENOPYRROLES AS HISTONE DEMETHYLASE INHIBITORS | ST EUROPEO DI ONCOLOGIA S R L (IT) | 2023-02-22 | — | — | EP | disclosed |
| US-11351168-B1 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | CELGENE CAR LLC (BM) | 2022-06-07 | — | — | US | disclosed |
| US-10828300-B2 | Substituted 2,4-diaminopyrimidines as kinase inhibitors | CELGENE CAR LLC (BM) | 2020-11-10 | — | — | US | disclosed |
| US-10596172-B2 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | CELGENE CAR LLC (BM) | 2020-03-24 | — | — | US | disclosed |
| EP-3549934-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | Celgene CAR LLC (BM) | 2019-10-09 | — | — | EP | disclosed |
| US-20190192512-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2019-06-27 | — | — | US | disclosed |
| US-20190117650-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2019-04-25 | — | — | US | disclosed |
| US-10183952-B2 | Thienopyrroles as histone demethylase inhibitors | ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) | 2019-01-22 | — | — | US | disclosed |
| EP-2519235-B1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE CAR LLC (BM) | 2018-11-21 | — | — | EP | disclosed |
| EP-2361248-B1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE CAR LLC (BM) | 2018-09-19 | — | — | EP | disclosed |
| EP-2519235-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | Avila Therapeutics, Inc. (US) | 2012-11-07 | — | — | EP | disclosed |
| EP-2361248-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | Avila Therapeutics, Inc. (US) | 2011-08-31 | — | — | EP | disclosed |
| WO-2011090760-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2011-07-28 | — | — | WO | disclosed |
| WO-2011090760-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2011-07-28 | — | — | WO | disclosed |
| US-20100249092-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100029610-A1 | Heteroaryl Compounds and Uses Thereof | AVILA THERAPEUTICS, INC. (US) | 2010-02-04 | — | — | US | disclosed |
| WO-2009158571-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS AND USES THEREOF (US) | 2009-12-30 | — | — | WO | disclosed |
| WO-2009158571-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS AND USES THEREOF (US) | 2009-12-30 | — | — | WO | disclosed |
| EP-1995241-A1 | Inhibitors of ion channels | ICAgen, Incorporated (US) | 2008-11-26 | — | — | EP | disclosed |
| WO-2008118758-A1 | INHIBITORS OF ION CHANNELS | ICAGEN, INC. (GB) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029610-A1 | Heteroaryl Compounds and Uses Thereof | ABCG2, CYP3A43, CYP3A5 | MAOA 331/4885MAOB 230/4885CHRNB4 3885/4885 |
| US-20100249092-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | MAOA 331/4885MAOB 230/4885CHRNB4 3885/4885 |
| US-11351168-B1 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | DCK, CDK2, DTYMK | MAOA 3352/4885MAOB 2519/4885CHRNB4 4647/4885 |
| US-20190192512-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | MAOA 331/4885MAOB 230/4885CHRNB4 3885/4885 |
| US-10828300-B2 | Substituted 2,4-diaminopyrimidines as kinase inhibitors | ABL1, DCK, ERBB2 | MAOA 2683/4885MAOB 2136/4885CHRNB4 4496/4885 |
| US-10183952-B2 | Thienopyrroles as histone demethylase inhibitors | KDM1A, KDM1B, KDM3A | MAOA 2008/4885MAOB 1546/4885CHRNB4 4259/4885 |
| US-20190117650-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | MAOA 331/4885MAOB 230/4885CHRNB4 3885/4885 |
| US-10596172-B2 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | DCK, CDK2, DTYMK | MAOA 3352/4885MAOB 2519/4885CHRNB4 4647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.